Last reviewed · How we verify
ASKG712
At a glance
| Generic name | ASKG712 |
|---|---|
| Also known as | AM712 |
| Sponsor | AskGene Pharma, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration (PHASE1)
- A Study of ASKG712 in Patients With Diabetic Macular Edema (PHASE1)
- Safety and Efficacy of AM712 in Patients with NAMD (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASKG712 CI brief — competitive landscape report
- ASKG712 updates RSS · CI watch RSS
- AskGene Pharma, Inc. portfolio CI